SII applies Novovax Covid-19 vaccine for trial nod.
Pune-based Serum Institute of India (SII) has filed an application to Drugs Controller General of India (DCGI) for conducting a small-scale domestic trial of Novovax Inc’s Covid-19 vaccine, which has been determined to be highly effective in UK trial standing at 89.3 % efficacy. SII’s chief executive officer, Adar Poonawalla stated that his company is…